Unknown

Dataset Information

0

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.


ABSTRACT: Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV for HCV genotype 1, and OBV/PTV/r + RBV for HCV genotype 4, in human immunodeficiency virus (HIV)-1 coinfected patients with or without compensated cirrhosis.TURQUOISE-I, Part 2 is a phase 3 multicenter study. Patients with or without cirrhosis were HCV treatment-naive or -experienced, on an HIV-1 antiretroviral regimen containing atazanavir, raltegravir, dolutegravir, or darunavir (for genotype 4 only), and had plasma HIV-1 ribonucleic acid <40 copies/mL at screening. Patients received OBV/PTV/r ± DSV ±RBV for 12 or 24 weeks.In total, 228 patients were treated according to guidelines. Sustained virologic response at posttreatment week 12 (SVR12) was achieved by 194 of 200 (97%) and 27 of 28 (96%) patients with HCV genotype 1 and genotype 4 infection, respectively. There were 2 virologic failures: 1 breakthrough and 1 relapse in a cirrhotic and a noncirrhotic patient with genotype 1b and 1a infection, respectively. One reinfection occurred at posttreatment week 12 in a genotype 1a-infected patient. Excluding nonvirologic failures, the SVR12 rates were 98% (genotype 1) and 100% (genotype 4). Adverse events were mostly mild in severity and did not lead to discontinuation. Laboratory abnormalities were rare.The OBV/PTV/r ±DSV was well tolerated and yielded high SVR12 rates in patients with HCV genotype 1 or genotype 4/HIV-1 coinfection. The OBV/PTV/r ± DSV ±RBV is a potent HCV treatment option for patients with HIV-1 coinfection, regardless of treatment experience.

SUBMITTER: Rockstroh JK 

PROVIDER: S-EPMC5597897 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.

Rockstroh Jürgen K JK   Orkin Chloe C   Viani Rolando M RM   Wyles David D   Luetkemeyer Anne F AF   Lazzarin Adriano A   Soto-Malave Ruth R   Nelson Mark R MR   Bhagani Sanjay R SR   Klinker Hartwig H F HHF   Rizzardini Giuliano G   Girard Pierre-Marie PM   Tural Cristina C   Shulman Nancy S NS   Mobashery Niloufar N   Hu Yiran B YB   Fredrick Linda M LM   Pilot-Matias Tami T   Trinh Roger R   Gane Edward E  

Open forum infectious diseases 20170722 3


<h4>Background</h4>Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV for HCV genotype 1, and OBV/PTV/r + RBV for HCV genotype 4, in human immunodeficiency virus (HIV)-1 coinfected patients with or without compensated cirrhosis.<h4>Methods</h4>TURQUOISE-I, Part 2 is a phase 3 multicenter study. Patients with or witho  ...[more]

Similar Datasets

| S-EPMC6175401 | biostudies-literature
| S-EPMC7126165 | biostudies-literature
| S-EPMC6365509 | biostudies-literature
| S-EPMC5306483 | biostudies-literature
| S-EPMC5853515 | biostudies-literature
| S-EPMC6211326 | biostudies-literature
| S-EPMC7467405 | biostudies-literature
| S-EPMC7687116 | biostudies-literature
| S-EPMC6850388 | biostudies-literature
| S-EPMC4706288 | biostudies-literature